Region — US. Neutral scientific reference — not offered for sale here.
Set region
Vallydia
ExploreShopToolsJournalTrustSearch ⌕
Explore  /  MOTS-c
Research reference — not for sale

MOTS-c

C
best evidence
Peptide⚠ WADA-banned
also called — MOTS-c · "Mitochondrial Open Reading Frame of the 12S rRNA type-c" · a mitochondrial-derived peptide (MDP). INCI: none
metabolicmitochondrialinsulin sensitivityexercise-mimetic (research context)

Research / reference — not for sale. No dosing, reconstitution, or administration is published (intentional). Neutral scientific reference only. Strong basic-science research; note the gap between mechanism/preclinical and human clinical proof.

In brief

MOTS-c is a 16-amino-acid mitochondrial-derived peptide, encoded in mtDNA and discovered in 2015, that regulates metabolism largely through the AMPK pathway. Its preclinical and mechanistic research is strong and coherent — multiple laboratories, top-tier journals — showing improved insulin sensitivity and metabolic homeostasis in animal models. But there are no published human efficacy RCTs of administering MOTS-c; in humans it remains interesting biology, not established therapy.

Legal standing, by region
European Union
Not FDA-approved (gray-market)

Not approved for human use; not eligible for magistral/officinal compounding. Research-chemical sale does not authorise human use.

United States · your region
Not FDA-approved (under review)

On the PCAC agenda for 23 July 2026 (with BPC-157/TB-500); removed from Category 2 in April 2026; FDA's pre-meeting briefing documents proposed not adding it to the 503A Bulks List. Advisory only; no final rule. Not approved.

International
Approved nowhere

Approved nowhere.

⚠ WADA-prohibited in sportSport: treated as WADA-prohibited (metabolic modulator / AMPK-activating "exercise-mimetic", Section S4). Athletes should treat it as banned.
Evidence, by outcome

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Insulin sensitivity / glucose metabolism / metabolic homeostasis
Mechanistically coherent and multi-lab, but no human efficacy RCT
Strong preclinical — Lee 2015 (Cell Metab) + multiple rodent studies (diet-induced obesity, T1D/T2D models) · Consistent improvement in animals
C
Exercise-mimetic / physical capacity
"Mimics exercise" ≠ "replaces exercise"; no human administration trial
Rodent studies + human observation (Reynolds 2021, Nat Commun: exercise raises muscle MOTS-c ~12-fold) · Suggestive
D
Aging / healthspan
Human data is correlational, not interventional
Preclinical + observational (levels decline with age; restored in aged mice by injection) · Suggestive
D
Marketed "anti-aging / metabolic fix" in humans
Human efficacy unproven; hype outruns evidence
None · Not demonstrated
F
Safety & long-term
WADA-banned; vendor guidance flags caution for cardiac arrhythmia, malignancy, pregnancy — i.e. unknown risk
No human efficacy/safety RCT · Unknown

Identity a 16-amino-acid peptide (< 40 aa → peptide) encoded by a short open reading frame nested inside the mitochondrial 12S rRNA gene (mtDNA — not the nuclear genome, a key reason for scientific interest). Identified in 2015 by Lee, Kim, Cohen and colleagues (USC) in a landmark Cell Metabolism paper; highly conserved across species; detected in tissues and circulation, with levels that decline with age. ## Development & history - MOTS-c belongs to a young class — mitochondrial-derived peptides (MDPs) — that opened with the discovery of Humanin (2003), the first evidence that the mitochondrial genome itself encodes bioactive signalling peptides.

  • MOTS-c was identified in 2015 by Changhan Lee, Su-Jeong Kim, Pinchas Cohen and colleagues at USC (in Cell Metabolism), by screening short open reading frames within mtDNA. It remains an academic-discovery / research compound: studied extensively in mechanism and in animals, but with no completed commercial drug-development programme or human efficacy trial to date. ## Mechanism (as proposed) MOTS-c acts largely via the folate–AICAR–AMPK axis — raising AICAR and activating AMPK, promoting GLUT4-mediated glucose uptake and insulin sensitivity. Under metabolic stress or exercise it translocates to the nucleus and regulates stress-adaptation genes bearing antioxidant response elements (ARE) — a "retrograde" mitochondria-to-nucleus signal. Well characterised in cells and animals; the relevance of exogenous MOTS-c in humans is unproven.
Sources — 4 cited
01Lee C, Zeng J, Drew BG, … Cohen P. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. (discovery paper)
02Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of… Nat Commun. 2021.
03Kim SJ, et al. (2017); Merry TL, et al. (2020) — AMPK/metabolic mechanism.
04MOTS-c: effects and mechanisms related to stress, metabolism and aging — review, PMC9854231; MOTS-c: a promising MDP for therapeutic exploitation — PMC9905433.
Review status
Not yet reviewed

A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (US review status evolving — re-check the July PCAC outcome and any Federal Register rule).

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
BPC-157B
Peptide
Explore by goal
MetabolicMitochondrial
Vallydia

A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.

Region — United States
ExploreRegisterCategoriesTrust & COA
ShopCosmetic peptidesJournal
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.

MOTS-c — evidence, uses & status · Vallydia